Colorado Care Network

Polygenic risk score

Patient cohortPopulation geneticsSeeking a lead#cohort-polygenic-riskPDF (members)

The anchor question: does this polygenic score change what we'd do for a well adult, beyond the family history and the clinical risk calculator? Sometimes, at the margin. One use the AHA suggests, as provisional guidance, is a coronary score as a risk-enhancing factor in middle-aged adults facing a borderline or intermediate-risk statin decision, and most of what we can defend sits close to that.1

Who this cohort covers

Well adults who hold a polygenic score for coronary disease, breast cancer, prostate cancer or type 2 diabetes, from a clinical lab or a consumer test, and adults who ask for one. It also covers carriers of a monogenic result (FH, BRCA1/2, Lynch) whose risk shifts with polygenic background. The monogenic workup itself lives on the hereditary cancer and comprehensive genetic risk maps; this map owns the score, what it adds and what it doesn't.

Two numbers frame the cohort. A genome-wide coronary score puts 8.0% of the population at more than threefold risk, 20 times the carrier frequency of monogenic variants with comparable risk.2 Across 926 scores in the PGS Catalog, the median detection rate at a 5% false-positive rate was 11%, and the top 2.5% of a coronary score held 7% of 10-year cases at age 50.3 The score finds some people at real risk and misses most of the people who will get the disease.

The evidence limits are plain. Scores built on today's data are several times more accurate in European ancestry, and accuracy falls with genetic distance from the training cohort, even within Europe.8 9 The case for acting on a coronary score rests on post hoc statin-trial subgroups and one LDL trial; the AHA calls the evidence for drug decisions observational.1 5 6 We use the score as one input to a decision that is already on the table, never as the reason to open one.

Care map

RoleYear 1, EstablishYear 2, TreatYear 3, Sustain
AnchorThree-generation pedigree with ages at onset for coronary disease, breast and prostate cancer and diabetes. Clinical risk first: pooled cohort equations and the breast and diabetes calculators. Name the decision the score could move before ordering one. If the patient brings a score, get the report: which score, the ancestry it was developed and validated in, and its performance metrics.16 17Fold the score into a decision it can move. One use the AHA suggests, as provisional guidance, is a coronary score as a risk enhancer in middle-aged adults at borderline or intermediate 10-year ASCVD risk.1 Shared decision with absolute numbers, not percentiles.Annual review. Recalculate clinical risk as age, lipids and blood pressure change. Revisit when the family history changes.
GeneticsMonogenic and polygenic variants both drive risk, so a score is not a substitute for monogenic testing when the pedigree meets criteria; send those patients down the hereditary cancer or comprehensive genetic risk map.1 7 Order a score only from a lab that reports its development ancestry and calibrates to the patient's genetic ancestry.16 17In monogenic carriers, polygenic background moved risk by age 75 from 17% to 78% for coronary disease, 13% to 76% for breast cancer and 11% to 80% for colon cancer.7 We use that to counsel. We don't use a low score to drop guideline management for a carrier; the AHA says whether an LDL-cholesterol score should allocate newer LDL-lowering drugs needs further study.1No cascade testing on a polygenic score; its value for relatives hasn't been worked out.1
SpecialistsUsually none.Preventive cardiology or lipid clinic when the score and clinical risk together point toward therapy and the patient wants a second read. High-risk breast clinic when an integrated model puts lifetime risk up. Urology for prostate screening decisions.As needed.
DiagnosticsLipid panel and A1c. Coronary calcium when the statin decision is borderline: in MESA, calcium beat the polygenic score for discrimination (C statistic 0.76 vs 0.69) and was the only one of the two to improve reclassification over the pooled cohort equations, with similar results in the Rotterdam Study; both cohorts were European-ancestry adults aged 45 to 79.4Breast: the best-validated score (313 SNPs) carries an odds ratio of 1.61 per SD and an AUC of 0.63 on its own.11 If one is used, run it through an integrated model with family history, moderate-penetrance genes, lifestyle factors and density; that combination stratifies best.12 Prostate: in BARCODE1, men in the top score decile had cancer on 40.0% of biopsies, but against MRI-based screening trials the strategy biopsied more men, found more low-grade and fewer high-grade cancers.13 14 We don't use a prostate score to start or skip PSA screening yet.Re-run clinical risk scores on schedule. Type 2 diabetes: adding a score to QDiabetes moved the C statistic from 0.8933 to 0.8945; the AHA calls high-risk identification of unclear value.1 15 Screen for diabetes on clinical grounds.
TherapiesStatin decision with the score in view: in three primary-prevention trials, the top quintile of genetic risk had greater relative and absolute statin benefit, an absolute risk reduction of 3.6% vs 1.3%.5Adherence and lipid response checked at each annual visit.
Behavioral health and nutritionLifestyle counseling regardless of score. At high genetic risk, a favorable lifestyle carried a 46% lower relative risk of coronary events.10Disclosing a genetic risk estimate with shared decision-making lowered LDL (96.5 vs 105.9 mg/dL) and increased statin starts (39% vs 22%), without changing diet or activity.6 Expect the score to move prescriptions more than habits.As needed.
CommunityA one-page handout on what a polygenic score is and isn't, given before ordering.

Visit one

The map above is the evidence. This is what to do with the patient in the room. Each line comes from the Year 1 column and carries the same citations.

AskThree-generation pedigree with ages at onset for coronary disease, breast and prostate cancer and diabetes. Any prior score or consumer test, and the actual report. Ancestry. The decision the patient hopes the score will inform.
ExamineBlood pressure, BMI and waist. Calculate the pooled cohort equations before anything genetic.
OrderLipid panel and A1c. Coronary calcium if the statin decision is borderline and hinges on it.4 A polygenic score only when a decision is on the table and only from a lab that reports development ancestry and calibrates to the patient's genetic ancestry.1 16 17 Monogenic testing instead when the pedigree meets criteria.
ReferUsually no one at visit one. Genetic counseling when the patient arrives with a consumer score and a frightening interpretation. Where: the counselor and esoteric assays rosters as they form, and imaging for coronary calcium.
Tell the patientA score shifts relative risk; it is not a diagnosis. Over ten years, most people with a high score won't get the disease, and most people who get it won't have a high score.3 It is less accurate outside European ancestry.8 9 Lifestyle matters at every level of genetic risk.10
DocumentThe score name and version, the lab, the ancestry calibration, the percentile and the absolute risk it implies, the clinical risk score, the decision made, and the date for the Year 1 review.

Roster for this cohort

Drawn from the esoteric assays roster (labs that publish a cash price, report development ancestry and calibrate to it), the counselor roster (cash-pay disclosure visits for polygenic and integrated risk), the advanced imaging roster (coronary calcium, breast MRI) and the specialist roster (preventive cardiology, lipid clinic, high-risk breast, urology). Forming; members propose and vet entries in the cohort's Slack channel.

Readings

References

  1. O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2022;146(8):e93-e118. doi:10.1161/CIR.0000000000001077
  2. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224. doi:10.1038/s41588-018-0183-z
  3. Hingorani AD, Gratton J, Finan C, et al. Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog. BMJ Med. 2023;2(1):e000554. doi:10.1136/bmjmed-2023-000554
  4. Khan SS, Post WS, Guo X, et al. Coronary artery calcium score and polygenic risk score for the prediction of coronary heart disease events. JAMA. 2023;329(20):1768-1777. doi:10.1001/jama.2023.7575
  5. Natarajan P, Young R, Stitziel NO, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135(22):2091-2101. doi:10.1161/CIRCULATIONAHA.116.024436
  6. Kullo IJ, Jouni H, Austin EE, et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES clinical trial). Circulation. 2016;133(12):1181-1188. doi:10.1161/CIRCULATIONAHA.115.020109
  7. Fahed AC, Wang M, Homburger JR, et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun. 2020;11(1):3635. doi:10.1038/s41467-020-17374-3
  8. Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591. doi:10.1038/s41588-019-0379-x
  9. Privé F, Aschard H, Carmi S, et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am J Hum Genet. 2022;109(1):12-23. doi:10.1016/j.ajhg.2021.11.008
  10. Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349-2358. doi:10.1056/NEJMoa1605086
  11. Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104(1):21-34. doi:10.1016/j.ajhg.2018.11.002
  12. Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019;21(8):1708-1718. doi:10.1038/s41436-018-0406-9
  13. McHugh JK, Bancroft EK, Saunders E, et al. Assessment of a polygenic risk score in screening for prostate cancer. N Engl J Med. 2025;392(14):1406-1417. doi:10.1056/NEJMoa2407934
  14. Sud A, McNeill A, Vickers AJ. Comparison of results from the BARCODE1 study and contemporary prostate cancer screening trials. Eur Urol Oncol. 2026;9(3):524-528. doi:10.1016/j.euo.2025.12.013
  15. Wright AK, Huang T, Carr MJ, et al. Clinical utility of self-reported sleep duration and insomnia symptoms in type 2 diabetes prediction. Diabetologia. 2025;68(11):2523-2534. doi:10.1007/s00125-025-06503-6
  16. Wand H, Lambert SA, Tamburro C, et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature. 2021;591(7849):211-219. doi:10.1038/s41586-021-03243-6
  17. Lennon NJ, Kottyan LC, Kachulis C, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat Med. 2024;30(2):480-487. doi:10.1038/s41591-024-02796-z

References retrieved from PubMed on 2026-10-30. Care maps are peer-authored clinical frameworks for network members, not individualized medical advice, and are reviewed at each yearly cycle.

Discuss this cohort in Slack

Colorado Care Network. Polygenic risk score. Version 2026-10-30.